Biotech Prescient Therapeutics (ASX: PTX) has successfully raised $7 million to fund an expanded pipeline of innovative cancer treatments. The clinical stage oncology company today…

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking up the microphone for another instalment of The Health Kick…

Prescient Therapeutics (ASX: PTX) Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the company’s novel approach to treating cancer using targeted and cellular…

Locally-listed small cap biotech company Prescient Therapeutics hopes to shift the conversation around cancer from treatments to cures, as it invests in a new-age technology showing early…

ASX-listed clinical-stage company Prescient Therapeutics Limited (ASX:PTX) is well-known for developing breakthrough targeted and personalised medicines approaches for the treatment of challenging cancer. On 14 August 2020,…

Prescient Therapeutics (ASX:PTX) has formed a cancer research partnership with the world-renowned Peter MacCallum Cancer Centre, ‘Peter Mac’, a leader in new clinical treatments for cancer…

Prescient Therapeutics (ASX: PTX) has moved closer to developing its unique CAR-T cancer technology after revealing a collaboration with the world-renowned Peter MacCallum Cancer Centre (Peter…

Special Report: Biotech company Prescient Therapeutics is advancing to next-stage trials for its personalised treatments for cancer and COVID-19 and has launched a capital raising…

Every year 45,000 of the most respected professionals in oncology gather at the American Society of Clinical Oncology (ASCO) annual meeting. This year the meeting…

Last month, the best and brightest minds in oncology gathered (virtually) for the American Society of Clinical Oncology (ASCO) annual conference. The conference was ablaze…